Evidence map›Paper›PMID 32908641›Full record

ArticleOxidative medicine and cellular longevity2020

MicroRNA-874-3p Aggravates Doxorubicin-Induced Renal Podocyte Injury via Targeting Methionine Sulfoxide Reductase B3.

Yan Dai, Meng Gao, Linxia Li, Zhang Mao, Lina Xu, Lianhong Yin, Yan Qi, Jinyong Peng

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Nonpolysaccharide fraction ofFrontiers in pharmacology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yan Dai *College of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Meng Gao *College of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Linxia LiCollege of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Zhang MaoCollege of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Lina XuCollege of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Lianhong YinCollege of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Yan QiCollege of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.
Jinyong PengCollege of Pharmacy, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian, China.ORCID https://orcid.org/0000-0002-6265-2667
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical application of doxorubicin (Dox) is limited due to its serious side effects including nephrotoxicity, and kidney podocytes play important roles in renal diseases. MicroRNAs (miRNAs) are critical regulators associated with human diseases. The purpose of this study was to explore a novel target in adjusting Dox-induced renal podocyte injury. Through a double luciferase reporter gene experiment, it was found that miR-874-3p directly targeted methionine sulfoxide reductase B3 (MsrB3). During the tests of miR-874-3p inhibitor and MsrB3 siRNA in human podocytes or miR-874-3p antagomir in mice, we found that the expression levels of downstream oxidative stress and apoptosis-related proteins were regulated by miR-874-3p/MsrB3 signal to alleviate or aggravate renal podocyte injury. The data in the present work showed that miR-874-3p aggravated Dox-caused renal podocyte injury by promoting apoptosis and oxidative damage via inhibiting MsrB3. Therefore, miR-874-3p/MsrB3 should be considered as a new therapeutic target in controlling renal podocyte injury induced by Dox.

Indexed as

AnimalsApoptosisBase SequenceCells, CulturedDown-RegulationDoxorubicinHumansMaleMethionine Sulfoxide ReductasesMice, Inbred C57BLMicroRNAsOxidative StressPodocytesSignal TransductionDoxorubicinmethionine sulfoxide reductase B3, mouseMethionine Sulfoxide ReductasesMicroRNAsMIRN874 microRNA, humanMIRN874 microRNA, mouseMSRB3 protein, human

Identifiers

PMID32908641
PMCPMC7450315
OpenAlexW3060997072

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.